Journal of the American Academy of Dermatology
Hidradenitis suppurativa in the pediatric population
Section snippets
Hidradenitis suppurativa in the pediatric population
Hidradenitis suppurativa (HS) is a chronic, recurrent inflammatory disorder of the hair follicles that affects apocrine gland–bearing sites, such as the axillae and inguinal and perianal areas.1 HS is uncommon in children, with onset generally occurring well after puberty, typically between 20 and 24 years of age.1 Prepubertal onset—before 11 years of age—is estimated to occur in 2% of patients with HS.2, 3 A recent publication reported that 66 of 855 patients (7.7%) had an onset of disease
Approach to managing pediatric hidradenitis suppurativa
HS can have a significant impact on quality of life, lifestyle, and self-esteem.1, 2 Moreover, painful lesions can limit activity, school attendance, and exercise, thereby contributing to obesity, which in turn exacerbates HS.1, 2
The medical management of HS in children is particularly challenging because of the scarcity of research and data on long-term outcomes in pediatric populations with this condition.13, 14 Most of the data guiding management derive from small cases series, expert
References (21)
Hidradenitis suppurativa in prepubescent and pubescent children
Clin Dermatol
(2015)- et al.
Correlation of early-onset hidradenitis suppurativa with stronger genetic susceptibility and more widespread involvement
J Am Acad Dermatol
(2015) - et al.
Gamma-secretase mutations in hidradenitis suppurativa: new insights into disease pathogenesis
J Invest Dermatol
(2013) - et al.
Infliximab therapy for patients with moderate to severe hidradenitis suppurativa: a randomized, double-blind, placebo-controlled crossover trial
J Am Acad Dermatol
(2010) - et al.
Prepubertal hidradenitis suppurativa: two case reports and review of the literature
Pediatr Dermatol
(1999) - et al.
Early-onset hidradenitis suppurativa
Clin Exp Dermatol
(2001) - et al.
Concurrent hidradenitis suppurativa, inflammatory acne, dissecting cellulitis of the scalp, and pyoderma gangrenosum in a 16-year-old boy
Pediatr Dermatol
(2014) - et al.
Prepubertal hidradenitis suppurativa successfully treated with botulinum toxin A
Dermatol Surg
(2009) - et al.
Hidradenitis suppurativa as a presenting feature of premature adrenarche
Br J Dermatol
(1993) - et al.
Hidradenitis suppurativa in a HIV-infected child
J Postgrad Med
(2012)
Cited by (64)
A report of 1290 pediatric hidradenitis suppurativa hospitalizations: A nationwide analysis from the Kids' Inpatient Database
2022, Journal of the American Academy of DermatologyBuilding a Multidisciplinary Hidradenitis Suppurativa Clinic
2022, A Comprehensive Guide to Hidradenitis SuppurativaTargeted Therapeutics: Biologics, Small Molecules
2022, A Comprehensive Guide to Hidradenitis SuppurativaPediatric Hidradenitis Suppurativa
2022, A Comprehensive Guide to Hidradenitis SuppurativaHidradenitis suppurativa in pediatric patients
2022, Journal of the American Academy of DermatologyCitation Excerpt :Therefore, within the tetracycline class, doxycycline is the preferred antibiotic choice for pediatric HS patients. Other antibiotics such as the combination of clindamycin and rifampicin, ertapenem, erythromycin, and metronidazole are suitable for children.2,56,57 Rifampicin, however, should be used with caution in areas endemic for tuberculosis because of the risk of drug resistance.
This publication was supported through funding provided by AbbVie Corporation.
Conflicts of interest: None declared.